Hypercalcemia of Malignancy

Seminars in Nephrology

Volumn 24, Issue 1, 2004, Pages 48-54

  Body, Jean Jacques ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; MITHRAMYCIN; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN ANTIBODY; RISEDRONIC ACID; SALCATONIN; ZOLEDRONIC ACID;

BONE TUMOR; CANCER; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERCALCEMIA; INCIDENCE; LETHALITY; LONG TERM CARE; NEPHROTOXICITY; OSTEOCLAST; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT;

EID: 0942268815     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnephrol.2003.08.015     Document Type: Article

References (36)

1. Body JJ: Current and future directions in medical therapy: Hypercalcemia. Cancer 88:3054-3058, 2000 (suppl)
2. Body JJ, Bartl R, Burckhardt P, et al: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16:3890-3899, 1998
3. De Wit S, Cleton F: Hypercalcemia in patients with breast cancer: A survival study. J Cancer Res Clin Oncol 120:610-614, 1994
4. Body JJ, Delmas PD: Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:471-475, 1992
5. Grill V, Ho P, Body JJ, et al: Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73:1309-1315, 1991
6. Dumon JC, Wantier H, Mathieu F, et al: Technical and clinical validation of a new immunoradiometric assay for human osteocalcin. Eur J Endocrinol 135:231-237, 1996
7. Singer F, Ritch P, Lad T, et al: Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med 151:471-476, 1991
8. Hosking D, Gilson D: Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. QJM 53:359-368, 1984
9. Gucalp R, Ritch P, Wiernik PH, et al: Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10:134-142, 1992
10. Dumon JC, Magritte A, Body JJ: Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 15:257-266, 1991
11. O'rourke N, Mccloskey E, Vasikaran S, et al: Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 67:560-563, 1993
12. Shah S, Hardy J, Rees E, et al: Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? Br J Cancer 86:1235-1237, 2002
13. Purohit O, Radstone C, Anthony C, et al: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72:1289-1293, 1995
14. Walker P, Watanabe S, Lawlor P, et al: Subcutaneous clodronate: A study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 8:915-916, 1997
15. Nussbaum S, Younger J, Vandepol C, et al: Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297-304, 1993
16. Body JJ, Dumon JC: Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of tumour type. Ann Oncol 5:359-363, 1994
17. Gurney H, Grill V, Martin TJ: Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 341:1611-1613, 1993
18. Rizzoli R, Thiebaud D, Bundred N, et al: Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 84:3545-3550, 1999
19. Body JJ, Louviaux I, Dumon JC: Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Support Care Cancer 8:398-404, 2000
20. Green J, Muller K, Jaeggi K: Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751, 1994
21. Pecherstorfer M, Herrmann Z, Body JJ, et al: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268-276, 1996
22. Ralston SH, Thiebaud D, Herrmann Z, et al: Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 75:295-300, 1997
23. Pecherstorfer M, Steinhauer E, Pawsey S: Ibandronic acid is more effective than pamidronate in lowering serum calcium in patients with severe hypercalcemia of malignancy (HCM) and has at least equal efficacy to pamidronate in HCM patients with lower baseline calcium levels: Results of a randomised, open label, comparative study. Proc ASCO 20:385A, 2001 (abstr)
24. Body JJ, Lortholary A, Romieu G, et al: A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14:1557-1561, 1999
25. Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567, 2001
26. Coleman RE: Pamidronate disodium in the treatment and management of hypercalcaemia. Rev Contemp Pharmacother 9:147-164, 1998
27. Machado CE, Flombaum CD: Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 45:175-179, 1996
28. Berenson JR, Rosen L, Vescio R, et al: Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37:285-290, 1997
29. Body JJ: Zoledronic acid: An advance in tumour bone disease and a new hope for osteoporosis. Expert Opin Pharmacother 4:567-580, 2003
30. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399-1405, 2003
31. Mancini I, Dumon JC, CsToth I, et al: Short-term treatment with the bisphosphonate ibandronate for opioid-resistant metastatic bone pain. Bone 30:B56, 2002 (abstr. suppl)
32. Body JJ, Mancini I: Bisphosphonates for cancer patients: Why, how and when? Support Care Cancer 10:399-407, 2002
33. Body JJ: Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97:859-865, 2003
34. McCloskey EV, Guest JF, Kanis JA: The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 61:1253-1274, 2001
35. Body JJ, Greipp P, Coleman R, et al: A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887-892, 2003 (suppl)
36. Body JJ: Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 28:49-53. 2001 (suppl)